Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Daoxiang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4436-1188; OpenAlex author ID A5026024685. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 10

  1. Tetrastigma hemsleyanum ELN-derived miR-396b suppresses pancreatic cancer cell proliferation by targeting IL33. Last author DOI 10.1016/j.bbrc.2026.154163↗
  2. Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. Last author DOI 10.1038/s42003-026-10009-1↗
  3. VDR Activation Suppresses Pancreatic Cancer Metastasis Through Inhibition of the ERK Signaling Pathway. Co-author DOI 10.3390/cancers18142296↗
  4. Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target. Co-author DOI 10.31083/fbl46316↗
  5. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
  6. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1053/j.gastro.2022.02.035↗
  7. The MK2/Hsp27 axis is a major survival mechanism for pancreatic ductal adenocarcinoma under genotoxic stress. Co-author DOI 10.1126/scitranslmed.abb5445↗
  8. Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-1366↗
  9. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Co-author DOI 10.1158/1535-7163.mct-17-1142↗
  10. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-1121↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mengjie Lv · 3 shared papers, 2025–2026 · strength 0.85
  2. Kian‐Huat Lim · 6 shared papers, 2017–2023 · strength 0.63
  3. Pengwei Cao · 2 shared papers, 2025–2026 · strength 0.46
  4. David G DeNardo · 3 shared papers, 2017–2023 · strength 0.35
  5. Patrick M. Grierson · 3 shared papers, 2018–2022 · strength 0.34
  6. Paarth B. Dodhiawala · 3 shared papers, 2018–2022 · strength 0.34
  7. Yanping Wang · 1 shared paper, 2026 · strength 0.33
  8. Lin Li · 2 shared papers, 2021–2022 · strength 0.26
  9. Fubao Liu · 1 shared paper, 2025 · strength 0.24
  10. Chuifang Kong · 1 shared paper, 2026 · strength 0.23
  11. Hongmei Jiang · 3 shared papers, 2017–2018 · strength 0.23
  12. Andrea Wang‐Gillam · 3 shared papers, 2017–2018 · strength 0.23
  13. John M. Baer · 1 shared paper, 2023 · strength 0.14
  14. William G. Hawkins · 1 shared paper, 2023 · strength 0.14
  15. Feng Gao · 1 shared paper, 2023 · strength 0.14
  16. Usman Younis Panni · 1 shared paper, 2023 · strength 0.14
  17. C. Alston James · 1 shared paper, 2023 · strength 0.14
  18. William E. Gillanders · 1 shared paper, 2023 · strength 0.14
  19. Varintra E. Lander · 1 shared paper, 2022 · strength 0.14
  20. Liang‐I Kang · 1 shared paper, 2022 · strength 0.14
  21. Vikas Somani · 1 shared paper, 2022 · strength 0.14
  22. Qiong Li · 1 shared paper, 2018 · strength 0.08
  23. Albert Craig Lockhart · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.